Amy E. Tapper - 15 Jul 2021 Form 3 Insider Report for Imago BioSciences, Inc.

Role
Senior Vice President, Non-Clinical and CMC
Signature
/s/ Matthew Plunkett, as Attorney-in-fact for Amy Tapper
Issuer symbol
N/A
Transactions as of
15 Jul 2021
Net transactions value
$0
Form type
3
Filing time
15 Jul 2021, 17:32:27 UTC
Next filing
19 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMGO Common Stock 119,047 15 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 5,952 $2.19 Direct F1
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 2,380 $2.27 Direct F1
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 65,732 $2.52 Direct F1
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 32,738 $1.52 Direct F1, F2
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 59,523 $2.10 Direct F1, F3
holding IMGO Stock Option (Right to Buy) 15 Jul 2021 Common Stock 23,809 $4.20 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 8.4-for-1 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
F2 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F3 The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F4 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Senior Vice President, Non-Clinical and CMC